trial · primary record
Inetetamab, pyrotinib, nab-paclitaxel
Breast Cancer
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2023-12-31 |
| Primary endpoint | Pathological complete response rate (pCR) |
| Registry ID | NCT05444998 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:03.788Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05444998
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.